Search clinical trials for: PRT064445/Rivaroxaban

Total 480 results

Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote

Healthy

United States
Alexion Pharmaceuticals
Population Health Research Institute; Portola Pharmaceuticals, LLC (a wholly...

Completed

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

Bleeding

United States, Belgium, Canada, France, Germany, Japan, Netherlands, Spain, United Kingdom
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

Healthy Volunteers

United States
Hospital Geral Roberto Santos

Terminated

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis (RIWA)

Stroke | Valve Heart Disease | Anticoagulants and Bleeding Disorders | Prostheses and Implants

Brazil
Portola Pharmaceuticals

Completed

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Bleeding

United States
Korea University Anam Hospital

Recruiting

Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation (REVISE-AF)

Atrial Fibrillation | Anticoagulant Adverse Reaction

Korea, Republic of
Doasense GmbH

Active, not recruiting

Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects (PHAPOCU)

Anticoagulant Therapy

Germany
China National Center for Cardiovascular Diseases

Not yet recruiting

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Stroke | Atrial Fibrillation | Major Adverse Cardiac Events | Anticoagulant Adverse Reaction
Bayer

Completed

A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men

Healthy Volunteers

Germany
The Affiliated Hospital of Qingdao University

Completed

Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers

Healthy Subjects

China
Bayer
Janssen R&D, L.L.C.

Completed

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Atrial Fibrillation

Japan
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)

Healthy Volunteers

United States
Bayer
Janssen Research & Development, LLC

Completed

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (X-PLORER)

Coronary Artery Disease | Cardiovascular Disease

Belgium, Netherlands
University Hospital, Grenoble

Completed

Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics (REVNEWANTICO)

Venous Thromboembolism

France
Addpharma Inc.

Completed

A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091

Embolism and Thrombosis

Korea, Republic of
Bayer

Completed

Bioequivalence Study of Rivaroxaban

Embolism, Atrial Fibrillation and Venous Thrombosis

Japan
Bayer

Completed

Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects

Embolism, Atrial Fibrillation and Venous Thrombosis

Japan
Second Xiangya Hospital of Central South University

Completed

Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome (H-REPLACE)

Myocardial Infarction | Myocardial Ischemia | Acute Coronary Syndrome | Unstable Angina

China
Centre Hospitalier Universitaire de Saint Etienne

Completed

Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects (RICHAR)

Healthy

France
Janssen Research & Development, LLC
Bayer

Completed

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER)

Heart Failure | Rheumatic Diseases | Respiratory Insufficiency | Infectious Diseases | Stroke Acute

United States, Poland, Ukraine, United Kingdom, Germany, Spain, Argentina, Belarus, Colombia, Israel, Mexico, Portugal, Bulgaria, Romania, Serbia, South Africa, Turkey, Canada, Australia, Netherlands, Denmark, Greece, Peru, Brazil, Russian... and more
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)

Healthy Volunteers
Bayer

Completed

An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study

Venous Thromboembolism

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Stroke | Embolism | Atrial Fibrillation

United States, Australia, France, Poland, Ukraine, United Kingdom, China, Belgium, Germany, Taiwan, Spain, Argentina, Colombia, Israel, Mexico, Bulgaria, India, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic... and more
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Bayer
Janssen Research & Development, LLC

Completed

Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEINJunior)

Venous Thrombosis

France, United States, Switzerland, Netherlands, Canada, Germany, Austria, Australia, Israel, Italy
Bayer
Janssen Research & Development, LLC; Colorado Prevention Center

Completed

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities (VOYAGER PAD)

Peripheral Artery Disease

Poland, Belgium, France, Spain, China, Korea, Republic of, United States, Switzerland, Estonia, Portugal, Japan, Hungary, Canada, Netherlands, Finland, Austria, United Kingdom, Germany, Czechia, Thailand, Brazil, Denmark, Italy, Russian... and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients (MAGELLAN)

Venous Thromboembolism

Belgium, France, Norway, Spain, China, Taiwan, United States, Switzerland, Colombia, Canada, Estonia, New Zealand, Finland, Italy, Portugal, Japan, Singapore, Germany, Greece, Australia, Sweden, Austria, Chile, Slovakia, United Kingdom, M... and more
Università degli Studi dell'Insubria
Ottawa Hospital Research Institute

Unknown

Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study

Portal Vein Thrombosis | Mesenteric Vein Thrombosis | Splenic Vein Thrombosis

Canada, Italy
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk (SHORT RUN AF)

Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement. (RECORD 4)

Venous Thromboembolism

Poland, United States, India, Denmark, Canada, Sweden, Bulgaria, Israel, Lithuania, Norway, Pakistan, Mexico, Sri Lanka
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Janssen Research & Development, LLC
Bayer

Completed

A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers

Healthy

Belgium
Walter Ageno

Unknown

Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis (RIDTS)

Deep Vein Thrombosis

Italy
Sherief Abd-Elsalam

Unknown

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Portal Vein Thrombosis

Egypt
University of Padova

Terminated

Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS)

Antiphospholipid Syndrome

Italy
University Hospital Inselspital, Berne
University of Lausanne Hospitals

Completed

PK of Rivaroxaban in Bariatric Patients - Extension

Prophylaxis of Venous Thromboembolism

Switzerland
AZ Sint-Jan AV
Onze Lieve Vrouw Hospital

Completed

Dose-finding of Rivaroxaban in Hemodialysis

Chronic Renal Failure

Belgium
Swiss Paraplegic Centre Nottwil

Withdrawn

Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury (rivaroxaban)

Thromboembolism | Spinal Cord Injuries

Switzerland
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Myocardial Infarction | Myocardial Ischemia | Acute Coronary Syndrome | Unstable Angina

United States, France, Poland, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Argentina, Chile, Colombia, Israel, Mexico, Portugal, Bulgaria, India, Malaysia, Romania, Russian Federation, Serbia, Turkey, Korea, Republic of, ... and more
Ottawa Hospital Research Institute

Recruiting

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters (TRIM-Line)

Cancer | Venous Thromboembolism

Canada
Bayer
Janssen Research & Development, LLC

Completed

Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (RITMUS-AF)

Non-valvular Atrial Fibrillation

Italy
Thomas Kander

Completed

The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM

Bleeding | Trauma | Hypothermia | Acidosis

Sweden
Hospital Alemão Oswaldo Cruz
Bayer; Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Brazilian... and other collaborators

Terminated

COVID-19 Antithrombotic Rivaroxaban Evaluation (CARE)

COVID-19

Brazil
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS)

Atrial Fibrillation

Austria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Slovenia, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Poland, Denmark, Sweden, Portugal, Ireland, Norway, Moldova, Republic of, Ukraine
Bayer
Janssen Research & Development, LLC; RTI Health Solutions

Completed

Patient and Physician Knowledge of Key Safety Messages

Anticoagulation

Germany, United Kingdom, France, Spain
Bayer
Janssen Research & Development, LLC

Completed

A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants

Thromboembolic Disorders

Germany
Bayer
Janssen Research & Development, LLC

Completed

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

Thrombosis

Canada, United States, Belgium, Spain, Italy, France, Finland, Hungary
Bayer
Janssen Research & Development, LLC

Completed

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Venous Thromboembolism

United States
Bayer
Janssen Research & Development, LLC

Completed

EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis (EINSTEINJr)

Venous Thromboembolism

Switzerland, Spain, United States, Austria, Italy, Russian Federation, United Kingdom, Brazil, Australia, Canada, Hungary, Netherlands, Israel, Poland, Japan

Search clinical trials for: PRT064445/Rivaroxaban

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations